Therapeutic effect of osteoporosis syndrome in gynecological tumor and breast cancer complicated with menopause

Abstract

Objective To analyze the clinical effects of osteoporosis syndrome on gynecologic tumors and breast cancer patients with menopause. Methods From December 2015 to December 2017 in the People’s Hospital of Xuchang, 46 gynecological tumors and 40 breast cancer patients with postmenopausal osteoporosis syndrome were selected as study subjects. The patients were divided into control group and observation group according to random number table, with 43 cases in each group. Both groups were given conventional radiotherapy, the patients in the control group were treated with conventional postmenopausal osteoporosis, and the patients in the observation group were treated with zoledronic acid on the basis of the treatment in the control group. The bone mineral density (BMD), bone mineral content (BMC), and osteocalcin (BGP) levels were compared before and after treatment in the two groups. The degree of joint pain and the incidence of adverse reactions were compared between the two groups. Results After treatment, the level of BMD in L1~L4, the proximal femur triangle (Ward ’s triangle) and the femoral neck of the patients in observation group were significantly higher than those in control group (P 0.05). After treatment, the indexes of both groups were significantly improved, and the improvement effect in observation group was significantly better than that in control group. The difference was significant (P 0.05). Conclusions Zoledronic acid in treatment of gynecologic tumors and breast cancer with postmenopausal osteoporosis syndrome patients can effectively improve the bone mineral density of the patients, relieve pain of thepatients, and have significant effects, high safety, and it is worthy of clinical promotion. Key words: Gynecological neoplasms; Breast cancer; Menopause; Osteoporosis syndrome; Zoledronic acid